04.17.26 -- STREAM Edition: Reprogramming T Cells And Reducing Manufacturing Costs With RegCell's Michael McCullar, Ph.D.

Find your winning clone and help fast track your progress. In the race to develop life changing therapies, you need to stay on track while satisfying performance and regulatory requirements. Efficiently achieving a robust cell line with high protein quality and yield is crucial for meeting your targets. Watch now to get an inside edge on the new Gibco CHOvantage™ GS kit. Learn more.

This presentation discusses the shift in pharmaceuticals from small-molecule drugs to protein biologics and the associated challenges, particularly the immunogenic response.

Explore when to intensify your processes, what challenges to expect, and how to prepare for a successful transition with expert insights to help guide your strategy and ensure smoother implementation.

Examine key advantages of single-use bioreactors, including scalable design and streamlined seed train processes for success.

 

 In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases.

Learn how ready-to-use solutions simplify downstream bioprocessing. Discover custom ethanol blends, aqueous formulations, and flexible packaging designed to reduce preparation time and safety risks.

See a shift toward animal‑free bioproduction, emphasizing plant‑based cell nutrients, sustainable manufacturing, supply‑chain security, and expert‑driven collaboration to support future therapeutic breakthroughs.